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Abstract. Here we presented a single electroencephalographic (EEG) marker for a neurophysiological assessment of Alzheimer’s
disease (AD) patients already diagnosed by current guidelines. The ability of the EEG marker to classify 127 AD individuals
and 121 matched cognitively intact normal elderly (Nold) individuals was tested. Furthermore, its relationship to AD patients’
cognitive status and structural brain integrity was examined. Low-resolution brain electromagnetic tomography (LORETA)
freeware estimated cortical sources of resting state eyes-closed EEG rhythms. The EEG marker was defined as the ratio between
the activity of parieto-occipital cortical sources of delta (2–4 Hz) and low-frequency alpha (8–10.5 Hz) rhythms. Results showed
77.2% of sensitivity in the recognition of the AD individuals; 65% of specificity in the recognition of the Nold individuals; and
0.75 of area under the receiver-operating characteristic curve. Compared to the AD subgroup with the EEG maker within one
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standard deviation of the Nold mean (EEG-), the AD subgroup with EEG+ showed lower global cognitive status, as revealed by
Mini-Mental State Evaluation score, and more abnormal values of white-matter and cerebrospinal fluid normalized volumes, as
revealed by structural magnetic resonance imaging. We posit that cognitive and functional status being equal, AD patients with
EEG+ should receive special clinical attention due to a neurophysiological “frailty”. EEG+ label can be also used in clinical trials
(i) to form homogeneous groups of AD patients diagnosed by current guidelines and (ii) as end-point to evaluate intervention
effects.
Keywords: Alpha rhythms, Alzheimer’s disease, delta rhythms, electroencephalography, low resolution brain electromagnetic
tomography (LORETA), neurophysiological assessment
INTRODUCTION
Recent guidelines propose a diagnostic algorithm
using physiopathological and topographical biomark-
ers of Alzheimer’s disease (AD) [1], which is the
most common cause of dementia in elderly subjects
[2, 3]. On one hand, the physiopathological biomark-
ers include the measures of A1-42, total tau, and
phospho-tau in cerebrospinal fluid (CSF) [23] and
the maps of positron emission tomography (PET)-
amyloid Pittsburg Compound B (PIB) showing the
deposition of A1-42 in the brain [4–6]. These phys-
iopathological markers would be mandatory to confirm
the diagnosis of prodromal AD or dementia of AD-
type in association with mild cognitive impairment
(MCI) and disabling cognitive deficits [1]. On the other
hand, the topographic biomarkers include the maps of
FDG-PET showing AD-like brain hypometabolism [7]
and the maps of magnetic resonance images (MRI)
of hippocampus or cortical atrophy [8–12]. These
topographic biomarkers would be especially useful
to predict and track disease progression, possibly
reflecting synaptic dysfunction and neural loss [1, 13].
However, none of the mentioned CSF, MRI, and PET
markers allows a clear-cut diagnosis or prediction of all
clinical presentations of AD. Furthermore, they can-
not be serially used along years for the evaluation
of AD individuals before and after pharmacological
and non-pharmacological interventions. Indeed, these
biomarkers are invasive (e.g., lumbar puncture for
CSF sampling; the injection of radioactive tracers in
PET procedures) and/or expensive (e.g., PET, MRI)
for serial recordings. Therefore, there is a quest for
new cost-effective, largely available, and non-invasive
biomarkers of AD to be used in serial recordings
and suitable for application to elderly subjects with
some cognitive impairment (i.e., not requiring the sub-
ject’s collaboration or prolonged states of complete
immobilization).
Electroencephalographic (EEG) markers potentially
fit the ideal features mentioned above [14]. The high
temporal resolution of EEG signals (e.g., milliseconds)
is ideal for investigating emerging features of brain
physiology, namely awake brain rhythms. In the condi-
tion of resting state eyes-closed, human brain produces
dominant oscillations at about 8–13 Hz, the so-called
alpha rhythms [15–18]. Cognitive processes such as
attention, perceptual binding, and working memory are
typically related to a reduction in power of resting state
alpha and beta (14–30 Hz) rhythms and to an increase
in power of delta (1–4 Hz), theta (4–7 Hz), and gamma
(30–70 Hz) rhythms [15–19].
Previous studies have shown that resting state eyes-
closed cortical EEG rhythms typically change across
physiological and pathological aging, with gradual
modifications visible as a variation in EEG power
(density) computed at scalp electrodes or in the activ-
ity of mathematically estimated EEG cortical sources
[14, 20–28]. When compared to normal elderly (Nold)
subjects, AD patients showed a power increase of
topographically widespread delta and theta (4–8 Hz)
rhythms and a power decrease of posterior alpha and/or
beta (13–30 Hz) rhythms [22–27, 29, 30]. In addition,
early stages of overt AD were typically associated
to slowing down in frequency of the power peak of
the resting state eyes-closed alpha rhythms, namely a
decrease of the individual alpha frequency (IAF) peak
[31]. In the AD patients, the mentioned abnormali-
ties of the EEG power correlated with several relevant
disease variables such as (i) markers of the amyloid
cascade, as measured in the CSF [32]; (ii) resting
state regional cerebral blood flow (rCBF), as measured
by single photon emission computerized tomography
(SPECT) or FDG-PET [26, 33]; (iii) the severity of
dementia, as measured by standard clinical scales [29];
and (iv) the severity of the cognitive impairment, as
indexed by Mini-Mental State Examination (MMSE)
and memory score [33–37]. Finally, a marked power
reduction of the posterior (i.e., especially occipital)
slow-frequency alpha rhythms characterized mild AD
patients when compared to patients with cerebrovas-
cular dementia, Parkinson’s disease with dementia,
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and frontotemporal dementia, whereas topographically
widespread theta rhythms showed higher power in
cerebrovascular dementia and Parkinson’s disease with
dementia patients than in AD patients [24, 31, 38]. Of
note, these findings are reported not to demonstrate
that spectral EEG markers can be used for diag-
nostic purposes (they do not reflect directly A1−42
or tau). Rather, they can reveal (not diagnostic as
not necessarily disease-specific) alterations of cortical
neural synchronization mechanisms underlying cor-
tical arousal related to low vigilance in groups of
individuals with dementia.
While the comparison of EEG markers between
groups of Nold, amnesic MCI, and AD subjects is quite
useful for the understanding of the neurophysiologic
correlates of AD, some important clinical applications
of biomarkers stem upon the property of EEG markers
to discriminate between patients and healthy controls
even if they do not have diagnostic purposes. For exam-
ple, EEG markers were proposed as enriching markers
in the neurophysiological assessment of adults with
mood and dementing disorders as well as in children
with attentional and learning disabilities [39]. Further-
more, there were also characteristic patterns of EEG
abnormalities in patients with alcoholic dementia [40].
Concerning the classification of Nold and AD individu-
als, it has been shown that spectral EEG power, or other
resting state EEG features, contributed to the discrimi-
nation of Nold from mild AD individuals with 94–45%
of success, from MCI to AD individuals with 92–78%
of success, and the conversion of MCI to AD status with
87–60% of success [23, 41–50]. Finally, these features
predicted AD in Nold subjects [51]. Despite the limited
sample size, some other results were especially inter-
esting. Surface topography of the multivariate phase
synchronization discriminated between 17 Nold and
17 AD individuals with accuracy up to 94% selecting
ad hoc EEG variables [50]. Furthermore, the combi-
nation of EEG markers and psychophysical indexes
improved the accuracy of the classification among 32
Nold, 13 MCI, and 3 mild AD subjects up to 94%
of specificity and 88% of sensitivity [52]. Finally,
compressed spectral arrays estimating mean frequency
analysis predicted dementia with Lewy bodies in 4
single patients originally diagnosed as AD [53].
The present study represents an important milestone
of the research program of our Consortium to test EEG
markers for several applications such as understand-
ing of the neurophysiology correlates of AD, possible
clinical management of patients, and definition of
biomarkers to be back-translated from AD patients to
preclinical mouse models of AD for drug discovery
[54]. In the framework of this research program, we
have previously used a freeware called low-resolution
brain electromagnetic tomography (LORETA) [55, 56]
to test the hypothesis that the activity of cortical sources
of delta and alpha rhythms in AD patients is related
atrophy of hippocampus [57], and cerebral cortex [58],
and global cognitive status as revealed by MMSE score
[59]. We have also successfully tested the hypothe-
sis that the activity of these cortical sources reflects
the deterioration of cognitive status in AD patients at
a follow up of about 12 months [60]. These findings
confirmed that our methodological approach of corti-
cal EEG source estimation can reveal (not diagnostic
as not necessarily disease-specific) alterations of cor-
tical neural synchronization mechanisms underlying
cortical arousal related to low vigilance in AD patients.
As a further milestone and absolute novelty, this
study presents and tests a single EEG marker based
on posterior delta and alpha cortical sources for a
neurophysiological enrichment of assessment phase in
AD patients already diagnosed by current guidelines
based on physiopathological biomarkers of AD and
neuropsychological testing [1]. The ability of the EEG
marker to classify AD individuals and matched Nold
individuals was tested. Furthermore, its relation to AD
patients’ cognitive status and structural brain integrity
was evaluated.
MATERIALS AND METHODS
Subjects
In the present study, we considered resting state
eyes-closed EEG data sets of 127 AD patients and 123
Nold subjects who were recruited by qualified clini-
cal recording units (IRCCS Fatebenefratelli Brescia,
Italy; IRCCS Oasi, Troina, Italy; Service of Neuro-
physiopathology of the University of Genova, Genova,
Italy; IRCCS “SDN”, Naples, Italy; Brain Dynamics,
Cognition and Complex Systems Research Center,
Istanbul Ku¨ltu¨r University, Istanbul, Turkey; Depart-
ment of Neurosciences, Dokuz Eylu¨l University, Izmir,
Turkey; Unified Hospitals of Foggia, Italy). The groups
were carefully matched as education, age and gender.
Table 1 summarizes the relevant demographic and
clinical (MMSE) [61] data of Nold and AD partici-
pants, together with the p value of the results of the
statistical comparisons between the groups. Indepen-
dent t-test was computed to evaluate the presence or
absence of statistically significant differences between
the two groups (i.e., Nold and AD) for age, educa-
tion, and MMSE (p < 0.05). Furthermore, Fisher exact
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Table 1
Demographic and clinical data of the Alzheimer’s disease (AD) and healthy elderly (Nold) subjects. Demographic and clinical data, together
with the p value of the results of the statistical comparisons between Nold subjects and AD patients. MMSE, Mini-Mental State Evaluation
Subjects (n) Gender (M/F) Age (years) Education (years) MMSE (score)
Nold 123 50/73 69.3 (±8.3 SD) 9.8 (±4.3 SD) 28.3 (±1.3 SD)
AD 127 50/77 69.3 (±8.2 SD) 9.9 (±4.8 SD) 20.4 (±4.0 SD)
Nold versus AD p = 0.9 p = 0.95 p = 0.75 p = 0.00001
test was computed to evaluate the presence or absence
of statistically significant differences between the two
groups for gender (p < 0.05). As expected, a statisti-
cally significant difference was found for the MMSE
score (p < 0.0001; higher MMSE score in the Nold
than in the AD group). On the contrary, no statisti-
cally significant difference was found for age, gender,
and education (p > 0.05).
The original studies including the subjects’ recruit-
ment and data collection were approved by the local
Institutional ethics committee, and followed prescrip-
tions of the Good Clinical Practice. Informed and overt
consent of subjects or subjects’ legal representatives
was in line with the Code of Ethics of the World Med-
ical Association (Declaration of Helsinki) and with
the standards established by the Author’s Institutional
Review Board.
Diagnostic criteria
Probable AD was diagnosed according to the criteria
of the Diagnostic and Statistical Manual of Men-
tal Disorders, fourth edition (DSM-IV-TR) (American
Psychiatric Association. Diagnostic and statistical
manual of mental disorders (IV-TR), 4th edn—text
revised. Washington, DC, 2000) and the National Insti-
tute of Neurological Disorders and Stroke–Alzheimer
Disease and Related Disorders (NINCDS–ADRDA)
working group [62]. These accepted criteria are ful-
filled in a two-step diagnostic process where there is
initial identification of a dementia syndrome and then
the application of criteria based on the clinical features
of the AD phenotype. The DSM-IV-TR criteria require
the presence of both a memory disorder and impair-
ment in at least one additional cognitive domain, both
of which interfere with social function or activities of
daily living.
Most of the AD patients (121 out of 127 patients,
namely more than 95%) followed a long-term treat-
ment with standard daily doses of acetylcholinesterase
inhibitors. In detail, they followed a treatment with
donepezil (73 patients; 5–10 mg/die), rivastigmine
(31 patients; 10 mg/die), galantamine (17 patients;
16–36 mg/die). The recruited AD patients underwent
general medical, neurological, neuropsychological
(ADNI battery), and psychiatric assessments. Patients
were rated with a number of standardized diagnostic
and severity instruments that included MMSE [61],
Clinical Dementia Rating Scale [63], Geriatric Depres-
sion Scale [64], Hachinski Ischemic Score [65], and
Instrumental Activities of Daily Living scale [66].
Neuroimaging diagnostic procedures (MRI) and com-
plete laboratory analyses were carried out to exclude
other causes of progressive or reversible dementias, in
order to have a clinically homogenous mild (first stage
of the disease, characterized by an objective deficit
on memory testing, confusion, difficulties in making
decisions, in finding the right word, and other mild
symptoms) to moderate AD group. Exclusion criteria
included any evidence of (i) frontotemporal dementia,
diagnosed according to current criteria [67], (ii) vascu-
lar dementia, diagnosed according to National Institute
of Neurological Disorders and Stroke and Association
Internationale pour la Recherche´ et l’Enseignement
en Neurosciences (NINDS-AIREN) criteria [68], (iii)
extra-pyramidal syndromes, (iv) reversible dementias
(including pseudodementia of depression), and (v)
Lewy body dementia, according to the criteria by
McKeith et al. [69].
A battery of neuropsychological tests was per-
formed to assess cognitive performance in several
domains including memory (delayed recall of Rey fig-
ures, [70]; Prose Memory Test delayed recall of a story,
[71]), language (1-minute verbal fluency for letters,
and 1-minute verbal fluency for fruits, animals or car
brands, [72]), executive function/attention (Trail Mak-
ing Test part A and B, [73]), and visuo-construction
abilities (copy of Rey figures [70]). Table 2 reports
the mean and standard deviation (SD) values of the
neuropsychological data.
The Nold subjects were recruited mostly from non-
consanguineous relatives of AD patients. All Nold
subjects underwent physical and neurological exam-
inations as well as cognitive screening (including
MMSE) to exclude any type of dementia. Among
them, those affected by chronic systemic illnesses (i.e.,
diabetes mellitus or organ failure) were excluded, as
were subjects receiving psychoactive drugs. The Nold
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Table 2
Mean and standard deviation (SD) values of the neuropsychological data of the AD patients
Neuropsychological Testing in the AD Subjects
Cognitive function Neuropsychological test Score
Global cognitive function MMSE 20.4 (±3.9 SD)
Structural verbal memory Prose Memory 3.0 (±2.8 SD)
Executive function Trail Making Test part A 125.8 (±80.9 SD)
Executive function Trail Making Test part B 329.0 (±285.9 SD)
Executive function Trail Making Test B-A 225.3 (±207.3 SD)
Visuospatial and visuo-constructive abilities Figure Rey copy 17.1 (±12.1 SD)
Visuospatial memory Figure Rey Recall 2.5 (±3.3 SD)
Language production Verbal fluency for letter 21.3 (±11.3 SD)
Language production Verbal fluency for category 19.1 (±7.8 SD)
Fig. 1. Recording sites of the 19 scalp electrodes positioned accord-
ing to the International 10–20 System (i.e., Fp1, Fp2, F7, F3, Fz, F4,
F8, T3, C3, Cz, C4, T4, T5, P3, Pz, P4, T6, O1, and O2).
subjects with history of present or previous neurologi-
cal or psychiatric disease were also excluded. All Nold
subjects had a Geriatric Depression Scale score lower
than 14 (no depression). When they showed no sign of
objective cognitive decline in the screening phase, they
received neither full neuropsychological examination
nor MRI scan.
EEG recordings
EEG data were recorded by the mentioned clinical
units while subjects were in the condition of rest-
ing state eyes-closed for a short period (i.e., about 5
minutes). EEG recordings were performed (0.3–70 Hz
bandpass) by 19 electrodes positioned according to
the international 10–20 system (i.e., Fp1, Fp2, F7,
F3, Fz, F4, F8, T3, C3, Cz, C4, T4, T5, P3, Pz, P4,
T6, O1, O2; see Fig. 1). Sampling frequency ranged
from 128 to 256 Hz across the mentioned clinical units,
according to their methodological facilities and stan-
dard local protocols. Analog high-bandpass was set
at 0.3 Hz, while analog low-bandpass depended on
the sampling frequency (e.g., 70 Hz for sampling fre-
quency at 256 Hz). Linked earlobe reference electrode
was appreciated but not mandatory, as all artifact-free
EEG data were off-line re-referenced to common aver-
age. To monitor eye movements, the horizontal and
vertical electro-oculogram (EOGs) were simultane-
ously recorded with the same recording parameters of
EEG.
The EEG recordings were performed in all subjects
in the late morning to minimize drowsiness. Further-
more, an operator controlled on-line the subject and
the EEG traces in order to keep constant the level of
vigilance.
Preliminary analysis of the EEG data
The recorded EEG data were segmented and ana-
lyzed off-line in consecutive 2 s epochs. We rejected
the EEG epochs associated with operator’s markers
indicating drowsiness, verbal warnings, eyes open-
ing, arm/hand movements, or other events (e.g., sweat,
sway, head movements) disturbing the EEG record-
ings. Furthermore, the EEG epochs with ocular (e.g.,
rapid eye opening despite the request to maintain
the eyes closed), muscular, and other types of arti-
facts were preliminarily identified by a computerized
automatic procedure. EEG epochs with sporadic and
well-shaped blinking artifacts (less than 15% of the
total) were, then, corrected by an autoregressive
method on the basis of the EOC activity [74]. Two
independent experimenters—blind to the diagnosis at
the time of the EEG analysis—manually revised the
EEG epochs accepted for further analysis. They also
performed a control analysis of subject’s vigilance
aimed at detecting EEG epochs with signs of sleep
such as K complexes, sleep spindles, and slow waves.
AU
TH
OR
 C
OP
Y
Journal Identification = JAD Article Identification = 143042 Date: October 29, 2015 Time: 1:47 pm
164 R. Lizio et al. / Resting State EEG Markers of Alzheimer’s Disease
The percentage values of the participants showing the
appearance of these EEG features were 2.8% for the
Nold group and 3.5% for the AD group. No statis-
tically significant difference between the two groups
was observed (Fisher exact test, p > 0.05 one-tailed).
The EEG epochs with signs of sleep were rejected. In
general, the amount of rejected EEG epochs was lower
than 20% of the recorded EEG data. In detail, the per-
centage of artifact-free EEG epochs, after the removal
of the EOG activity, was 85% for the Nold group and
81% for the AD group. A statistical procedure showed
no statistically significant difference of that percentage
between the two groups (Fisher exact test, p > 0.05 one-
tailed). No EEG individual dataset accepted for final
spectral analysis included less than 60 artifact-free 2-s
EEG epochs.
All artifact-free EEG epochs were re-referenced to
common average for further analysis.
Spectral analysis of the EEG data
A standard digital FFT-based power spectrum anal-
ysis (Welch technique, Hanning windowing function,
no phase shift) was used to calculate the IAF peak,
which is a frequency of special importance associated
with maximum power of resting state eyes-closed EEG
rhythms [15]. This standard FFT procedure was imple-
mented by a homemade software developed under
Matlab 6.5 (Mathworks Inc., Natrick, MA; Welch
technique, Hanning windowing function, no phase
shift, 1-Hz frequency resolution). More specifically,
Hanning windowing function (i.e., 1-s windows), no
overlapping windows, and no phase shift were used.
We opted for two non-overlapping time windows of
1 s each, rather than for 1 time window of 2 s in any
artifact-free EEG epoch lasting 2 s. This maximized the
reliability of the computation of EEG mean power den-
sity and set the frequency resolution of IAF to 1 Hz (the
use of time windows of 2 s would have allowed a fre-
quency resolution of 0.5 Hz). The frequency bands of
interest for the present study were delta (2–4 Hz), theta
(4–8 Hz), alpha 1 (8–10.5 Hz), alpha 2 (10.5–13 Hz),
beta 1 (13–20 Hz), beta 2 (20–30 Hz), and gamma
(30–40 Hz), in continuity with a bulk of previous stud-
ies of our research group [24, 54, 56, 57, 59].
For a given subject, the IAF peak was defined as
the frequency bin having the maximum power den-
sity averaged over all electrodes in the range from 6 to
14 Hz [15]. Mean IAF peak was 9.3 Hz (±1.2 standard
deviation, SD) in the Nold subjects and 8.6 Hz (±1.5
SD) in the AD subjects, in line with the fact that early
stages of AD are typically associated to a decrease
of the IAF peak in the EEG power density spectrum
[31]. Most of AD (70.5%) and Nold (91.2%) individ-
uals had IAF peaks within alpha 1 band (8–10.5 Hz)
used to form the present EEG marker (vide infra). For
control purposes, independent t-test was computed to
evaluate the presence or absence of statistically signif-
icant differences between the two groups (i.e., Nold
and AD) for IAF peak (p < 0.05). A statistically sig-
nificant difference was found (p < 0.0001). Therefore,
the IAF peak served as a covariate in subsequent statis-
tics to minimize the possibility that differences in the
IAF peak could confound the comparisons of the alpha
sources between the Nold and AD groups.
Cortical source of EEG rhythms as computed by
LORETA
Low resolution electromagnetic source tomogra-
phy (LORETA) as provided at http://www.unizh.
ch/keyinst/NewLORETA/LORETA01.htm was used
for the estimation of cortical sources of scalp EEG
power density [55, 75, 76]. LORETA is a source recon-
struction technique belonging to a family of linear
inverse solution procedures modeling 3D distributions
of EEG sources [55, 75, 76]. LORETA computes
3D linear solutions (LORETA solutions) for the EEG
inverse problem within a 3-shell spherical head model
including scalp, skull, and brain compartments. The
brain compartment is restricted to the cortical gray
matter/hippocampus of a head model co-registered to
the Talairach probability brain atlas and digitized at
the Brain Imaging Center of the Montreal Neurolog-
ical Institute [77]. This compartment includes 2,394
voxels (7 mm resolution), each voxel containing an
equivalent current dipole fixed as position and orien-
tation. LORETA computes relative currents for z, x,
and y components of any dipole. LORETA solutions
consisted of voxel current density values able to pre-
dict EEG spectral power density at scalp electrodes.
Being a reference-free method of EEG analysis, in that
one obtains the same LORETA source distribution for
EEG data referenced to any reference electrode includ-
ing common average. To enhance the topographical
results, a spatial normalization was obtained by nor-
malizing the LORETA current density at each voxel
for the LORETA power density averaged across all
frequencies (0.5–40 Hz) and across all 2,394 voxels of
the brain volume. After the normalization, the solutions
lost the original physical dimension and were repre-
sented by an arbitrary unit scale. As an advantage, this
procedure reduced inter-subject variability [78, 79].
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Table 3
Regions of interest (ROIs) used for the estimation of cortical sources
of resting state eyes closed EEG rhythms in the present study. Any
ROI is defined by some Brodmann areas of cerebral source space
of low-resolution brain electromagnetic tomography (LORETA)
freeware
Brodmann Areas into the ROIs
Frontal 8, 9, 10, 11, 44, 45, 46, 47
Central 1, 2, 3, 4, 6
Parietal 5, 7, 30, 39, 40, 43
Temporal 20, 21, 22, 37, 38, 41, 42
Occipital 17, 18, 19
Limbic 31, 32, 33, 34, 35, 36
Solutions of the EEG inverse problem are under-
determined and ill conditioned when the number of
spatial samples (electrodes) is lower than that of the
unknown samples (current density at each voxel).
In order to properly address this problem, the corti-
cal LORETA solutions predicting scalp EEG spectral
power density were regularized to estimate distributed
rather than pointed EEG source patterns [55, 75, 76].
In line with the low spatial resolution of the adopted
technique, we used our MATLAB software to average
LORETA solutions across all voxels of a given cortical
macroregion of interest (ROI) such as frontal, cen-
tral, parietal, occipital, temporal, and limbic regions
of the brain model (Table 3 lists the ROIs in terms
of Brodmann areas as defined within the LORETA
source space). For the present LORETA cortical source
estimation, a frequency resolution of 0.5 Hz was used,
namely the maximum frequency resolution allowed by
the use of 2-s artifact free EEG epochs. In this line, the
frequency bands of interest were delta (2–4 Hz), theta
(4–8 Hz), alpha 1 (8–10.5 Hz), alpha 2 (10.5–13 Hz),
beta 1 (13–20 Hz), beta 2 (20–30 Hz), and gamma
(30–40 Hz), in continuity with a bulk of previous
studies of our research group [24, 54, 56, 57, 59].
Statistical analysis of the LORETA solutions
To compare the spatial distribution of resting
state EEG sources between the Nold and the AD
group, the regional normalized source solutions (i.e.,
source activity) were used as a dependent vari-
able for an ANOVA design using subjects’ IAF
peak as covariate (STATISTICA 12; StatSoft Inc.,
http://www.statsoft.com). The ANOVA factors (lev-
els) were Group (Nold, AD), ROI (frontal, central,
parietal, occipital, temporal, limbic), and Band (delta,
theta, alpha 1, alpha 2, beta 1, beta 2, gamma).
Mauchly’s test evaluated the sphericity assumption.
Correction of the degrees of freedom was made with
the Greenhouse-Geisser procedure. Duncan test was
used for post-hoc comparisons (p < 0.05). The planned
post-hoc testing evaluated the prediction of regional
changes in activity of the source solutions between
the Nold and the AD group. Specifically, we expected:
(i) a statistical 3-way interaction effect including the
factors Group, ROI, and Band (p < 0.05); (ii) a post-
hoc test indicating statistically significant differences
of the regional normalized LORETA solutions with the
pattern Nold /= AD (Duncan test,p < 0.05, one tailed).
Computation of the EEG marker
Based on a review of the literature (see the “Intro-
duction”) and, in particular, of our previous EEG
field studies with the present methodological approach
[24, 54, 56, 57, 59], the present EEG marker was
defined as the ratio between the activity of parieto-
occipital (LORETA) cortical sources of delta and alpha
1 rhythms. This ratio was the dependent variable in the
main statistical analyses.
Accuracy of the EEG marker in the discrimination
between Nold and AD individuals
As a first part of the testing, the EEG marker was
used as a discriminant (not diagnostic as not neces-
sarily disease-specific) variable for the classification
between the Nold and AD individuals. The correct
blind classification of this EEG marker was performed
by Matlab 2010b software (Mathworks Inc., Natrick,
MA, USA) for the production of receiver operat-
ing characteristic (ROC) curves [80]. The following
indexes measured the classification performance of the
above binary classification:
• Sensitivity: it measures the rate of the AD sub-
jects who were correctly classified as AD (i.e.,
“true positive rate” in the signal detection theory).
• Specificity: it measures the rate of the Nold (con-
trol) subjects who were correctly classified as
Nold (i.e., “true negative rate” in the signal detec-
tion theory).
• Accuracy: the mean between the sensitivity and
specificity.
• AUC: Area under the ROC curve.
Evaluation of the relationship between the EEG
marker and relevant variables of AD
Based on the values of the EEG marker (i.e., ratio
between the activity of parieto-occipital delta and
alpha 1 sources), we defined AD individuals with the
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EEG marker “positive” (i.e., EEG+) as those having
marker values equal or higher than the mean plus one
standard deviation (SD) of the marker value in the Nold
reference population. This EEG+ condition is expected
to indicate abnormal values of the EEG marker in AD
individuals as compared to the Nold group. In this line,
the AD individuals with the EEG marker “negative”
(i.e., EEG-) were those having marker values within the
mean plus one SD of the marker value in the Nold ref-
erence population. As mentioned above, EEG+ should
not be considered as a diagnostic marker as the rela-
tive abnormalities of EEG rhythms could not reflect
changes of pathophysiological markers of AD accord-
ing to the guidelines by Dubois and colleagues [1].
To test the hypothesis that the EEG+ condition is
related to relevant disease variables in AD patients,
the MMSE score was compared between the AD sub-
group with EEG+ and the AD subgroup with EEG-
by Student test (p < 0.05, one tailed; STATISTICA 12;
StatSoft Inc.). The hypothesis would be confirmed by
a t value indicating a statistically significant lower
MMSE score in the AD subgroup with EEG+ than in
the AD subgroup with EEG- (p < 0.05 one tailed).
In the same line, we also hypothesized that the
EEG+ condition is related to more abnormal brain
structure in AD patients. To test this hypothesis,
cortical gray matter (GM), subcortical white matter
(WM), and CSF normalized volumes were estimated
in 77 out of the 127 AD patients, namely those hav-
ing T1- and T2-weigthed structural MRIs available.
These MRIs had been acquired following standard
research settings mostly by 1.5 T scanners at the
following clinical centers: IRCCS Fatebenefratelli
Brescia, Italy; IRCCS Oasi, Troina, Italy; Service of
Neurophysiopathology of the University of Genova,
Genova, Italy; IRCCS “SDN”, Naples, Italy; Brain
Dynamics, Cognition and Complex Systems Research
Center, Istanbul Ku¨ltu¨r University, Istanbul, Turkey;
Department of Neurosciences, Dokuz Eylu¨l Univer-
sity, Izmir, Turkey; Unified Hospitals of Foggia, Italy.
Some of these units collected the MRIs following the
ADNI protocols available at http://www.adni-info.org
(e.g., IRCCS “SDN” of Naples; United Hospital of
University of Foggia; IRCCS Oasi of Troina; Ser-
vice of Neurophysiopathology of the University of
Genova).
The MRI scans were visually inspected to ver-
ify the absence of structural abnormalities or
technical artifacts. Centralized MRI data analy-
sis was performed by MATLAB 7.1 (MathWorks,
Natick, MA) and SPM8 (Wellcome Dept. Cogn.
Neurol., London; http://www.fil.ion.ucl.ac.uk/spm).
Specifically, the processing of the MRI data was as
follows: the native MRI data of each patient were par-
titioned into GM, WM, and CSF compartments and
spatially normalized to fit a standard labeled template,
obtaining the transformation matrix [81]. This labeled
template was based on averaged high-resolution MRIs
acquired from 24 subjects, comprising anatomic chan-
nels (T1, T2, and proton density weighted), tissue
channels (cerebrospinal fluid-CSF probability, gray
matter-GM probability, white matter-WM probability,
and tissue labels), and the LPBA40 cortical parcel-
lation map, based on the LONI Probabilistic Brain
Atlas of 40 subjects [82] and identifying 56 brain
structures. Second, the inverse of the transformation
matrix was used to map the 56 atlas brain struc-
tures to the partitioned GM compartment, enabling
volume quantification of each structure. Thirdly, a
homemade MATLAB script was used to calculate the
volume of cortical GM, and of the entire (cortical and
subcortical) GM, WM, and CSF compartments. The
normalized volumes of cortical GM, and WM and
CSF compartments were obtained dividing the vol-
ume of each compartment by the total (GM, WM and
CSF) volume. Of note, the above procedure seemed
to be more appropriate than voxel-based morphome-
try [83] for the analysis of the relationship between
low-resolution (LORETA) EEG source estimates and
MRI markers. Indeed, voxel-based morphometry is
based on an intrinsically high-resolution voxel-by-
voxel approach.
The comparison of the GM, WM, and CSF nor-
malized volumes in the AD subgroup with EEG+
and in the AD subgroup with EEG- was performed
by a two-way ANOVA using the normalized volume
as a dependent variable (p < 0.05; STATISTICA 12,
StatSoft Inc.). The ANOVA factor were Group (AD
with EEG+, AD with EEG-; independent variable)
and Brain volume (GM, WM, and CSF). Mauchly’s
test evaluated the sphericity assumption. Correction of
the degrees of freedom was made with Greenhouse-
Geisser procedure when appropriate. The Duncan
test was used for post-hoc comparisons (p < 0.05,
one tailed). The hypothesis would be confirmed by
the following two statistical results: (i) a statistical
ANOVA effect including the factor Group (p < 0.05)
and (ii) a post-hoc test indicating statistically signif-
icant lower GM and WM normalized volumes in the
AD subgroup with EEG+ than in the AD subgroup
with EEG- (p < 0.05 one tailed) and/or a statisti-
cally significant higher CSF normalized volume in
the former than in the latter subgroup (p < 0.05 one
tailed).
AU
TH
OR
 C
OP
Y
Journal Identification = JAD Article Identification = 143042 Date: October 29, 2015 Time: 1:47 pm
R. Lizio et al. / Resting State EEG Markers of Alzheimer’s Disease 167
Fig. 2. Grand average of LORETA solutions (i.e., normalized relative current density at the cortical voxels or source activity) modeling the
distributed EEG sources for delta, theta, alpha 1, alpha 2, beta 1, beta 2, and gamma bands in the Nold and in the AD group. The left side of
the maps (top view) corresponds to the left hemisphere. Legend: LORETA, low-resolution brain electromagnetic tomography. Color scale: all
values of source activity were scaled based on the averaged maximum value (i.e., alpha 1 activity of occipital sources in Nold).
RESULTS
Topography of the EEG cortical sources as
estimated by LORETA
For illustrative purpose, Fig. 2 maps the grand aver-
age of the LORETA solutions (i.e., relative power
current density at cortical voxels or source activity),
modeling the distributed EEG cortical sources for
delta, theta, alpha 1, alpha 2, beta 1, beta 2, and gamma
bands in the Nold and in the AD group. The Nold group
presented alpha 1 sources with the maximal activity
distributed in the posterior regions. Delta, theta, and
alpha 2 sources had moderate activity when compared
to the alpha 1 sources. Finally, the beta 1, beta 2, and
gamma sources were characterized by lowest activ-
ity. Noteworthy, the relative low activity of beta 2
(20–30 Hz) and gamma (30–40 Hz) cortical sources in
both groups leads confirmed that the current EEG data
used for source estimation were related to a condi-
tion of effective resting state and muscle relaxation.
Compared to the Nold group, the AD group showed a
strong activity reduction of posterior alpha sources,
along with an activity increase of widespread delta
sources.
Statistical analysis of the EEG cortical sources
Figure 3 shows the grand average of the activity
of regional EEG cortical sources relative to a
statistically significant ANOVA interaction effect
(F(30,7440) = 18.7; p < 0.0001) among the factors
Group (Nold, AD), Band (delta, theta, alpha 1, alpha 2,
beta 1, beta 2, gamma), and ROI (frontal, cen-
tral, parietal, occipital, temporal, limbic). The IAF
peak was used as a covariate. Planned post-hoc test-
ing (see Table 4) disclosed that the pattern Nold
> AD was fitted by central, frontal, parietal, occipi-
tal, temporal, and limbic alpha 1 sources (p < 0.05)
as well as parietal, occipital, temporal, and limbic
alpha 2 sources (p < 0.005). On the contrary, the
pattern Nold < AD was fitted by central, frontal, pari-
etal, occipital, temporal, and limbic delta sources
(p < 0.0001) as well as frontal, temporal, and limbic
theta sources (p < 0.005). The present results confirm
that parieto-occipital cortical sources of resting state
eyes-closed delta and alpha 1 rhythms are good candi-
dates for the computation of a valid EEG marker for
a neurophysiological assessment of AD patients. We
tested the value of this EEG marker in the following
sections.
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Fig. 3. Mean values of regional normalized LORETA solutions (i.e., source activity) relative to a statistically significant ANOVA interaction
effect (F(30, 7440) = 18.7; p < 0.0001) among the factors Group (AD, Nold), Band (delta, theta, alpha 1, alpha 2, beta 1, beta 2, gamma),
and ROI (central, frontal, parietal, occipital, temporal, limbic). Subjects’ individual alpha frequency (IAF) was used as a covariate. Legend:
the rectangles indicate the cortical regions and frequency bands in which LORETA solutions (i.e., source activity) presented the statistically
significant LORETA pattern of source activity Nold /= AD (Duncan test, p < 0.05).
Table 4
p values (Duncan post hoc) of the ANOVA showing a statistically significant interaction effect (F(30,7440) = 18.7; p < 0.0001) among the factors
Group (Nold, AD), Band (delta, theta, alpha 1, alpha 2, beta 1, beta 2, gamma), and ROI (frontal, central, parietal, occipital, temporal, limbic)
Duncan Post Hoc Test Comparing EEGS Sources in the Nold and AD Subjects
Delta Theta Alpha1 Alpha2 Beta1 Beta2 Gamma
Central p = 0.0001 n.s. p = 0.000002 n.s. n.s. n.s. n.s.
Frontal p = 0.000002 p = 0.0006 p = 0.01 n.s. n.s. n.s. n.s.
Parietal p = 0.000002 n.s. p = 0.000001 p = 0.000001 n.s. n.s. n.s.
Occipital p = 0.000002 n.s. p = 0.000002 p = 0.000002 n.s. n.s. n.s.
Temporal p = 0.000001 p = 0.0008 p = 0.000002 p = 0.002 n.s. n.s. n.s.
Limbic p = 0.000004 p = 0.003 p = 0.000001 p = 0.000004 n.s. n.s. n.s.
Accuracy of the EEG marker in the classification
between Nold and AD individuals
The EEG marker served as a discriminant variable
for the ROC analysis in the classification between the
Nold and AD individuals. Results showed 77.2% of
sensitivity in the correct recognition of the AD patients
(true positive rate, expressed as a percentage), 65%
of specificity in the correct recognition of the Nold
subjects (true negative rate), 71.2% of accuracy (mean
between the sensitivity and specificity), and 0.75 of
area under the ROC curve (see Fig. 4 and Table 5).
These results indicate that the EEG marker allows a
moderate classification of the individuals of the two
populations (i.e., Nold, AD).
Relationship between the EEG marker and
relevant variables of AD
The MMSE score as an index of global cognition
was on average 21.2 (±3.4 SD) in the AD subgroup
with EEG- (n = 86) and 18.7 (±4.7 SD) in the AD
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Fig. 4. ROC (receiver operating characteristic) curve illustrating the
performance of the EEG marker in the classification of the Nold
and AD individuals. Area under curve (AUC) was of 0.75 (mod-
erate classification performance). True positive rate indicates the
probability of the correct classification of AD datasets (sensitivity),
whereas false positive rate indicates the probability of the incorrectly
classification of Nold datasets (1-specificity).
subgroup with EEG+ (n = 41). Student test indicated
that the difference of the MMSE score between the two
AD subgroups was statistically significant (p < 0.001),
in line with the working hypothesis.
Concerning the MRI markers of structural brain
integrity, the GM, WM, and CSF normalized vol-
umes of the AD subgroup with EEG- (n = 36) were
on average 0.164 (±0.02 SD), 0.263 (±0.02 SD),
and 0.423 (±0.04 SD), respectively. Furthermore, they
were 0.158 (±0.03 SD), 0.245 (±0.02 SD), and 0.449
(±0.05 SD), respectively, in the AD subgroup with
EEG+(n = 31). The ANOVA design showed a statisti-
cally significant interaction (F(2,130) = 4.8, p < 0.01)
between the factors Group (AD subgroup with EEG-,
AD subgroup with EEG+; independent variable) and
Volume (GM, WM, CSF). Duncan post-hoc testing
indicated that the WM normalized volume was lower
Fig. 5. Mean and SD values of cortical gray matter (GM), subcortical
white-matter (WM), and cerebrospinal fluid (CSF) normalized vol-
umes as indexes of brain structural integrity extracted by magnetic
resonance imaging (MRI) in a subpopulation of 77 AD patients of
the present study (those having MRI data associated to EEG record-
ings). The values are reported in the AD subgroup negative to the
EEG marker (EEG-; n = 36) and in the AD subgroup positive to
the EEG marker (EEG+; n = 31). These values refer to an ANOVA
design showing a statistically significant interaction (F(2,130) = 4.8,
p < 0.001) between the factors Group (AD subgroup with EEG-,
AD subgroup with EEG+; independent variable) and Volume (GM,
WM, CSF). Asterisks indicate the p level of the statistical differ-
ences between the two AD subgroups obtained by Duncan post-hoc
testing.
in the AD subgroup with EEG+ compared to the AD
subgroup with EEG- (p < 0.05), while the CSF normal-
ized volume was higher in the AD subgroup with EEG+
compared to the AD subgroup with EEG- (p < 0.001;
see Fig. 5 and Table 6). Instead, the between-groups
difference in the GM volume did not reach the statis-
tical significance (p > 0.05).
Control analyses
It is well known that MMSE score is an important
element (e.g., among laboratory tests, patient history,
neuropsychological testing, etc.) used by physicians to
formulate a diagnosis of Nold or AD. Consequently,
MMSE score is able to classify the present Nold and
AD individuals. Keeping this fact in mind, we per-
formed a control ROC analysis of subjects’ MMSE
score to produce a “ceiling” classification rate of Nold
and AD individuals as a reference for the evaluation of
Table 5
Results of the classification between the Nold and AD individuals of the present study based on an EEG marker defined as the ratio of the
activity between parieto-occipital cortical (LORETA) sources of delta and alpha 1 rhythms. This marker served as a discriminant variable for
the analysis by receiver operating characteristic (ROC) curves
Classification Rate of the EEG marker
Subjects (n) Classification as AD (%) Classification as Nold (%)
Nold 123 35 65
AD 127 77.2 22.8
AU
TH
OR
 C
OP
Y
Journal Identification = JAD Article Identification = 143042 Date: October 29, 2015 Time: 1:47 pm
170 R. Lizio et al. / Resting State EEG Markers of Alzheimer’s Disease
Table 6
Demographic and clinical data of the groups of AD patients (AD- and AD+). Demographic and clinical data, together with the p value of the
results of the statistical comparisons between the groups of AD patients negative (EEG-) and positive (EEG+) to the EEG marker who had
markers of brain integrity as revealed by magnetic resonance imaging
Subjects (n) Gender (M/F) Age (years) Education (years) MMSE (score)
AD- 36 10/26 70.6 (±8.9 SD) 7.8 (±3.9 SD) 19.9 (±2.4 SD)
AD+ 31 12/19 68.5 (±7.1 SD) 7.2 (±3.9 SD) 17.8 (±4.0 SD)
AD- versus AD+ p = 0.4 p = 0.2 p = 0.6 p = 0.01
the present EEG marker. Results showed 92.9% of sen-
sitivity (true positive rate, expressed as a percentage),
100% of specificity (true negative rate), 96.4% of accu-
racy (mean between the sensitivity and specificity), and
0.98 of area under the ROC curve.
Reliability of the present results was tested by a con-
trol analysis evaluating reproducibility of the cortical
estimation of resting state eyes-closed EEG rhythms
in the Nold subjects. Firstly, we randomly divided all
Nold subjects in two subgroups (i.e., A and B), each
formed by 50% of the Nold subjects. Secondly, all
artifact-free EEG epochs of any Nold subject were
divided in two halves: (i) the EEG epochs of first
recording half and (ii) the EEG epochs of second
recording half. Thirdly, the EEG cortical sources of any
Nold subject were estimated two times, one time for
the EEG epochs of the first recording half and another
time for the EEG epochs of the second recording half.
Fourthly, we formed two populations of control Nold
EEG datasets. The “first control Nold population” was
formed by (i) EEG cortical sources estimated from
EEG epochs of the first recording half in the subgroup
A and (ii) EEG cortical sources estimated from EEG
epochs of the second recording half in the subgroup B.
The “second control Nold population” was formed by
(i) EEG cortical sources estimated from EEG epochs
of the second recording half in the subgroup A and
(ii) EEG cortical sources estimated from EEG epochs
of the first recording half in the subgroup B. Fifthly,
we compared the spatial distribution of resting state
EEG cortical sources between the “first control Nold
population” and the “second control Nold population”.
The statistical procedure was like that used in the main
analysis of the EEG cortical sources between Nold
and AD populations. Specifically, the regional nor-
malized source solutions (i.e., source activity) were
used as a dependent variable for an ANOVA design
(STATISTICA 12; StatSoft Inc.). The ANOVA factors
(levels) were Group (“first control Nold population”,
“second control Nold population”), ROI (frontal, cen-
tral, parietal, occipital, temporal, limbic), and Band
(delta, theta, alpha 1, alpha 2, beta 1, beta 2, gamma).
Mauchly’s test evaluated the sphericity assumption.
Correction of the degrees of freedom was made with
the Greenhouse-Geisser procedure. Duncan test was
used for post-hoc comparisons (p < 0.05). Figure 6
shows the mean activity of regional EEG cortical
sources in the two groups (“first control Nold popula-
tion”, “second control Nold population”) for the ROIs
(frontal, central, parietal, occipital, temporal, limbic),
and for the frequency bands of interest (delta, theta,
alpha 1, alpha 2, beta 1, beta 2, gamma). Note that the
EEG cortical source profiles of the two groups were
practically identical. As expected, there was no statis-
tically significant ANOVA effect including the factor
Group (p > 0.7), in line with a good reproducibility of
the present EEG cortical source estimates.
Another test on the reliability of the present results
was performed by a control analysis of correlation
between the activity of parieto-occipital cortical delta
or alpha 1 sources and MMSE score in all Nold
and AD subjects. The control results did show a sta-
tistically significant negative correlation between the
activity of parieto-occipital delta sources and MMSE
score (r = –0.26; p = 0.00003; Spearman test). The
higher the activity of pathological parieto-occipital
delta sources, the lower the MMSE score. In the same
vein, there was a statistically significant positive cor-
relation between the activity of parieto-occipital alpha
1 sources and MMSE score (r = 0.34; p = 0.00001;
Spearman test). The higher the activity of dominant
parieto-occipital alpha 1 sources, the higher the MMSE
score. These results pointed to a clear statistical rela-
tionship between these sources and global cognitive
status in the Nold and AD subjects.
DISCUSSION
As mentioned above, the present Consortium
designed an EEG research program for several neu-
rophysiological, clinical, and preclinical applications
in the AD field [54]. Most EEG markers were derived
by EEG recordings in the condition of resting state
eyes-closed, which reflect the fluctuation of sub-
ject’s cortical arousal and vigilance. This experimental
AU
TH
OR
 C
OP
Y
Journal Identification = JAD Article Identification = 143042 Date: October 29, 2015 Time: 1:47 pm
R. Lizio et al. / Resting State EEG Markers of Alzheimer’s Disease 171
Fig. 6. Mean values of regional normalized LORETA solutions (i.e., source activity) in the two subgroups of Nold population for the ROIs
(frontal, central, parietal, occipital, temporal, limbic) and for the frequency bands of interest (delta, theta, alpha 1, alpha 2, beta 1, beta 2, gamma).
Of note, the subgroups (i.e., A and B) of Nold population were formed each formed by 50% of the Nold subjects. All artifact-free EEG epochs
of any Nold subject were divided in two halves: (i) the EEG epochs of first recording half and (ii) the EEG epochs of second recording half.
The EEG cortical sources of any Nold subject were estimated two times, one time for the EEG epochs of the first recording half and another
time for the EEG epochs of the second recording half. The “first control Nold population” (i.e., A) was formed by (i) EEG cortical sources
estimated from EEG epochs of the first recording half in the subgroup A and (ii) EEG cortical sources estimated from EEG epochs of the second
recording half in the subgroup B. The “second control Nold population” (i.e., B) was formed by (i) EEG cortical sources estimated from EEG
epochs of the second recording half in the subgroup A and (ii) EEG cortical sources estimated from EEG epochs of the first recording half in
the subgroup B.
condition has the advantage that it does not require
stimulation devices or electronic systems for the con-
trol of the subject’s behavior during EEG recordings
and is easy to set up. For the human part of the men-
tioned research program, we used LORETA freeware
[55] for the estimation of cortical sources of rest-
ing state eyes-closed EEG rhythms. In this study, we
presented and tested a single EEG marker for a neu-
rophysiological assessment of AD patients. The EEG
marker was computed as the ratio between the activ-
ity of parieto-occipital delta and low-frequency alpha
sources. Its value was tested as ability to classify sin-
gle Nold and AD individuals. Furthermore, we tested
its relationship to AD patients’ cognitive status and
structural brain integrity.
A preliminary control analysis showed that com-
pared to the Nold group, the AD group was
characterized by an activity increase of the posterior
sources of delta rhythms as well as by a power decrease
of the posterior sources of low-frequency alpha
rhythms. Noteworthy, occipital (LORETA) source
power of these rhythms revealed the highest statisti-
cal differences between the Nold and the AD group
(p < 0.0001), in line with previous studies using the
same methodology [24, 28, 56, 57, 71, 84, 99]. The
present control results confirmed the promising fea-
tures of the ratio between the activity of the occipital
(LORETA) sources of delta and low-frequency alpha
rhythms for a simple neurophysiological assessment
of AD individuals.
The first novel finding of the present study was
the classification rate between the Nold and AD indi-
viduals by the new single EEG marker derived by
our previous EEG studies in AD [54–60]. The results
showed 77.2% of sensitivity in the correct recognition
of the AD patients, 65% of specificity in the correct
recognition of the Nold subjects, and 0.75 of area under
the ROC curve, which corresponds to a moderate per-
formance for a binary classifier [80, 85]. These results
show an intermediate classification rate with reference
to previous EEG studies reporting the following per-
centages of correct discrimination: 89–45% between
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Nold and AD individuals, 92–78% between MCI and
AD individuals, and 87–60% for the conversion of MCI
subjects to AD status [23, 41–43, 45, 47–49, 86, 87].
The present moderate classification rate was reason-
ably due to the use of a priori single EEG marker for
the discrimination purpose and to the intrinsic limita-
tion of the classification procedure. Noteworthy, the
ROC analysis of MMSE score provided reference sen-
sitivity of 92.9% even if this score was used as a
diagnostic variable. Furthermore, no severe AD patient
(typically showing abnormal delta and alpha rhythms)
was enrolled for the present study. Finally, the present
AD patients were under treatment by standard long-
term acetylcholinesterase inhibitors, which is expected
to partially preserve EEG rhythms [59, 88–90].
The present novel EEG approach is based on a sin-
gle marker and no mathematical classifier, features
quite convenient for a practical use in a clinical con-
text. The present approach parallels multivariate EEG
approaches in which several EEG markers are given
as an input to principal or independent component
analyses. Afterwards, the outcome of these analyses is
typically given as an input to trained mathematical clas-
sifiers such as support vector machines, random forest
or artificial neural networks. Noteworthy, multivariate
EEG approaches have previously shown classifica-
tion accuracies higher than 85% in AD patients (see
above literature review). In general, the univariate
and the multivariate EEG approaches are not alter-
native and could be chosen as a function of local
resources and aims. The present single EEG marker
may be easily computed and used for a neurophysio-
logical assessment in daily clinical practice, as it does
not require complex mathematical platforms and ref-
erence databases. The multivariate EEG approach is
more complex and may be used in memory clinics
with personnel expert in the use of mathematical plat-
forms and reference databases. Both EEG approaches
could be used for research applications and clinical
trials. Finally, the present single EEG marker has the
advantage to be obtained by a deterministic procedure
independent of rater judgment, compared to traditional
visual judgment of expert neurologists of resting state
EEG traces. Future studies should compare over time
the single EEG marker, standard multivariate spectral
EEG markers, report of traditional visual judgment of
EEG activity, and MMSE score to test their clinical
value in the management of AD patients.
A second novel finding of the present study was
the comparison of MMSE score and MRI indexes
of structural brain integrity between the AD sub-
group positive (EEG+) and the AD subgroup negative
(EEG-) to the single EEG marker. The results showed
that the MMSE score and WM normalized volume
were lower in the AD subgroup with EEG+ compared
to the AD subgroup with EEG-, while the oppo-
site was true for the CSF normalized volume. These
results were in line with the hypothesis that the EEG+
condition is related to a more abnormal global cog-
nition and brain structure in AD patients. Therefore,
the present single EEG marker was associated to rel-
evant disease variables in the AD patients, leading
support to the idea that it may enrich the clinical pic-
ture of AD individuals typically based on diagnosis
performed by physiopathological biomarkers of AD
and neuropsychological testing according to the cur-
rent guidelines [1], disease duration, global cognitive
status, and impairment in the activities of daily life. It
can be speculated that the present EEG marker may
better define the brain function in AD patients with the
same cognitive and functional impairment and with the
same cognitive reserve as indexed by education years
and kind of jobs and intellectual occupations in the sub-
ject’s life. The cognitive reserve is usually related to
brain neural/synaptic redundancy and ability of plastic
remodeling that result from the interaction of genetic,
epigenetic, and environmental (i.e., prolonged periods
of educational and intellectual activities) factors affect-
ing good maturation of brain in terms of myelination of
neural fibers and robust WM connections among brain
regions. [91–93]. It is important in the assessment of
AD patients as it reflects the adaptive processes main-
taining a quasi-stable cognitive status despite ongoing
physiopathological disease processes [91–93]. Keep-
ing in mind the present results, it can be speculated that
cognition, daily life abilities, and cognitive reserve sta-
tus being equal [1], an AD patient with the additional
feature of EEG positivity (i.e., EEG+) may reflect more
neurophysiological “frailty” and less functional brain
reserve than an AD patient with EEG negativity (i.e.,
EEG-). In this line of speculation, the AD patient with
the additional feature of neurophysiological “frailty”
should receive more therapeutic resources and clinical
attention.
As a final methodological remark, a minority of the
EEG datasets of the present study (less than 20%) was
acquired by 128-Hz sampling frequency, in line with
the methodological facilities and standard local pro-
tocols of some clinical recording units participating
to this study (some EEG datasets of the present study
were collected in the framework of local clinical rou-
tine). In this regard, it should be remarked that the
use of 128-Hz sampling frequency was suboptimal for
a perfect reconstruction of EEG signal up to 40 Hz
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and for avoiding some distortion of low-band frequen-
cies (the so called aliasing issue). Ideally, one should
set a factor from 4 to 5 between the low-pass limit of
analog bandpass filter (e.g., 40 Hz) and the EEG sam-
pling frequency (e.g., from 160 to 200 Hz rather than
128 Hz of the present study). Setting a factor from 4
to 5 would have permitted to fully take into account
the high frequency cutoffs of the roll-off analog filter
and to perfectly reconstruct the highest frequency EEG
contents up to 40 Hz (i.e., gamma rhythms). Aware of
the above considerations, we still decided to use the
EEG datasets recorded by 128-Hz sampling frequency
as the present working hypothesis did focus on an EEG
marker computed based on cortical sources of parieto-
occipital delta and alpha rhythms, in line with previous
EEG evidence of our Consortium [55–59]. In this line,
cortical sources of high frequency EEG rhythms (i.e.,
gamma) were presented just to show as EEG power
density decreased after its peak at alpha frequencies,
as expected when subjects are properly relaxed during
EEG recordings performed in the condition of resting
state eyes closed. Of note, this condition of low vigi-
lance should not progress to drowsiness or sleep onset
during EEG recording. To mitigate this confound, the
duration of the present EEG recordings was relatively
short (e.g., about 5 minutes) and an experimenter mon-
itored general subject’s behavior. Furthermore, EEG
epochs were carefully revised to reject those with EEG
signs of drowsiness and sleep. Indeed, very few sub-
jects showed initial EEG signs of sleep (i.e., about 3%).
Finally, reliability of the present results was also tested
by a control analysis of correlation between the activ-
ity of parieto-occipital cortical delta or alpha 1 sources
and the MMSE score in all Nold and AD subjects.
Results showed that the higher the activity of patho-
logical parieto-occipital delta sources, the lower the
MMSE score. Furthermore, the higher the activity of
dominant parieto-occipital alpha 1 sources, the higher
the MMSE score. These results cannot be explained
by EEG sampling frequency or drowsiness and sleep
during the experiments.
CONCLUSIONS
Can a single EEG marker provide a neurophysiolog-
ical enrichment of the assessment phase in AD patients
already diagnosed by current guidelines based on
physiopathological biomarkers of AD and neuropsy-
chological testing [1]? Based on previous evidence
[56–60], we defined a single EEG marker as the
ratio between the activity of parieto-occipital cortical
sources of delta and low-frequency alpha rhythms. The
EEG marker showed 77.2% of sensitivity in the recog-
nition of the AD individuals, 65% of specificity in the
recognition of the Nold individuals, and 0.75 of area
under the ROC curve. This finding suggests that this
marker can reveal (not diagnostic as not necessarily
disease-specific) alterations of EEG rhythms related
to low vigilance in single AD individuals. Compared
to the AD subgroup with the EEG marker within one
standard deviation of the Nold mean (EEG-), the AD
subgroup with EEG+ showed lower global cognitive
status and WM normalized volume, while the opposite
was true for the CSF normalized volume. We conclude
that this EEG marker may unveil a neurophysiological
“frailty” in AD patients already diagnosed by cur-
rent guidelines [1]. In this line, cognitive (e.g., MMSE
score) and functional status being equal, AD patients
with EEG+ (i.e., neurophysiological “frailty”) may
need special clinical attention. Future studies should
test if this EEG marker is useful as an instrumental
secondary endpoint to test drugs against prodromal
AD or dementia due to AD and is able to monitor dis-
ease progression with a substantial added value with
respect to traditional visual inspection of EEG activity
and MMSE score.
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